document.write("\n \n \n
<\/td>\n <\/td>\n <\/td>\n <\/tr>\n
<\/td>\n <\/td>\n \n \n \n
<\/a>Present and Future Management Options for Clostridium difficile Infection
<\/font><\/b><\/a>\n
\n DALE N. GERDING, MD<\/strong>
\nHines Veterans Affairs Hospital and Loyola University Chicago
\nStritch School of Medicine
\nHines, Illinois
\n
\nTreatment selection for Clostridium difficile infection (CDI) has become more complex despite the lack of new FDA-approved treatments. Two investigational agents show promise for reduction of the high rate of CDI recurrence; fidaxomicin—a poorly absorbed macrocyclic antimicrobial agent—and IV monoclonal antibodies directed at toxins A and B.<\/span>\n<\/td>\n <\/tr>\n <\/table><\/td>\n 		<\/td>\n <\/td>\n <\/tr>\n
<\/td>\n <\/td>\n <\/td>\n <\/tr>\n<\/table>\n");